You can buy or sell GLMD and other stocks, options, ETFs, and crypto commission-free!
Galmed Pharmaceuticals Ltd. Ordinary Shares, also called Galmed Pharmaceuticals, is a clinical-stage biopharmaceutical company. Read More It focuses on the development of the liver targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. The Aramchol is a synthetic conjugate of cholic acid, or a type of bile acid, and arachidic acid, or a type of saturated fatty acid, both of which, in their non-synthetic forms, are naturally occurring. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
Tel Aviv, Tel Aviv
52 Week High
52 Week Low
Seeking AlphaMay 7
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q1 2019 Results - Earnings Call Transcript
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Q1 2019 Earnings Conference Call May 7, 2019 8:30 AM ET Company Participants Allen Baharaff - President & Chief Executive Officer Liat Hayardeny - Chief Scientific Officer Tali Gorfine - Chief Medical Officer Yohai Stenzler - Chief Financial Officer Conference Call Participants Steve Seedhouse - Raymond James Mayank Mamtani - B. Riley Thomas Yip - H.C Operator Good day, and welcome to the Galmed Conference Call to discuss Financial Results for the First Q...
Galmed Pharmaceuticals (GLMD) Reports Q1 Loss, Misses Revenue Estimates
Galmed Pharmaceuticals (GLMD) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.17 per share a year ago.
Yahoo FinanceMay 7
Galmed Pharmaceuticals: 1Q Earnings Snapshot
TEL AVIV, Israel (AP) _ Galmed Pharmaceuticals Ltd. (GLMD) on Tuesday reported a loss of $3.5 million in its first quarter. On a per-share basis, the Tel Aviv, Israel-based company said it had a loss of 17 cents. The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 19 cents per share. Galmed Pharmaceuticals shares have increased 10% since the beginning of the year. The stock has increased 27% in the last 12 months. _____ ...
-$0.20 per share
-$0.17 per share